Oncodesign appoints Karine Lignel as Group Development Director


PARIS & DIJON, France – (COMMERCIAL THREAD) – Regulatory news:

ONCODESIGN (ALONC – FR0011766229) (Paris: ALONC), a biopharmaceutical group specializing in precision medicine, announces the appointment of Karine Lignel as Senior Executive Vice President – Group Chief Development Officer.

“We are honored and proud to welcome Karine Lignel to our ranks. She knows our company well, having worked with and supported it with a lot of commitment through her role as director, representing Crédit Mutuel Innovation since 2008 ” declared Philippe Genne, Founder, Chairman and CEO of Oncodesign. “Her skills in venture capital – where she has excelled for more than 20 years in biotechnology and finance – combined with her in-depth knowledge of the company and its strategy will help us to accelerate our development in a major and tangible way. We plan to accelerate external growth by acquiring companies, technologies and complementary products in line with our objectives. At the crossroads of these skills, the new role of Karine Lignel is a very strong asset for Oncodesign, and we are convinced that she will succeed in her mission.

Karine Lignel, new Director of Group Development at Oncodesign, adds: “I am delighted to join Oncodesign in an operational role. I have known the company and its leaders for a very long time, and I have always admired their objectives and the way they operate. In my role as shareholder representative, I have witnessed the tremendous development of Oncodesign, and I am proud to now be able to work even more closely with them, bringing my own development and strategy skills. Participating in the discovery of new therapies, especially against cancer, is such an important mission for me, and it means that I will be fully engaged and highly motivated.

Karine Lignel, 53, is the former President of Crédit Mutuel Innovation (€ 250 million in equity dedicated to investments in innovative companies), a subsidiary of Crédit Mutuel Equity. During her career, she has followed and participated in the development of more than 60 technology companies, mainly in health, including Nanobiotix, Tissium, Maat Pharma, Endodiag and Global Bioenergies.

Prior to her career of more than twenty years in venture capital, which she began at Créagro, Karine Lignel had held technical and managerial positions in the industry, notably at Barry Callebaut.

Engineer ENSIA (AgroParisTech), Karine Lignel holds a Master in Management and Finance from IGIA, as well as a certification of administrator from ESSEC.

About Oncodesign: www.oncodesign.com

Oncodesign is a biopharmaceutical company specializing in precision medicine, founded in 1995 by its current CEO and majority shareholder. It has been listed on the Euronext growth market since April 2014. Its mission is to discover effective therapies to fight cancer and other diseases without a therapeutic solution. Drawing on its unique experience, enriched by more than 1,000 customers – including the world’s largest pharmaceutical companies – and relying on a unique technological platform combining artificial intelligence, medicinal chemistry, pharmacology, regulatory bioanalysis and medical imaging of cutting edge, Oncodesign is able to select new therapeutic targets, then design and develop potential preclinical candidates through to the clinical phase. Oncodesign has configured its organization to offer innovative services to its customers and licenses for its proprietary molecules. Applied to kinase inhibitors – molecules which represent a market estimated at more than 65 billion dollars by 2027 and nearly 25% of the pharmaceutical industry’s R&D investments – Oncodesign’s technology has already made it possible to target several molecules of interest with high therapeutic potential. potential, both in oncology and outside, and has signed partnerships with international pharmaceutical groups. Based in Dijon, France, at the heart of the CHU and the Paris-Saclay complex, Oncodesign has 230 employees in three Business Units (BU) – Service, Biotech and Artificial Intelligence – and has subsidiaries in Canada and the United States.


This document contains forward-looking statements and estimates concerning the financial condition, results of operations, strategy, plans and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates may be recognized by the use of words such as, but not limited to, “believe”, “anticipate”, “anticipate”, “expect”, “plan”, “ plan ”,“ intend ”,“ estimate ”,“ may ”,“ will ”,“ continue ”and similar expressions. These include all matters which are not historical facts. These statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors which were considered reasonable when made, but which may prove to be inaccurate. Actual events are difficult to predict and may depend on factors beyond the control of the Company. Therefore, the actual results, financial conditions, performance or achievements of the Company, or the results of the industry, may differ materially from future results, performance or achievements as expressed or implied by such statements, forecasts and estimates. In light of these uncertainties, no representation is made as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of publication of this document. The Company disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any change in the Company’s expectations in this regard, or any change in the events, conditions or circumstances on which such statements, forecasts or estimates are based. , except in cases where required by French law.


Sara H. Byrd

Leave a Reply

Your email address will not be published.